![A semaglutide injection pen](https://www.uc.edu/news/articles/2024/08/n21273650/jcr:content/image.img.cq5dam.thumbnail.500.500.jpg/1724940827155.jpg)
How Ozempic is affecting people with eating disorders and the food industry
UC expert discusses need for more research with WVXU's Cincinnati Edition
GLP-1 drugs, sold under brand names including Ozempic and Wegovy, are growing more popular for weight loss. At the same time, experts say the drugs are dramatically altering people's relationship with food and the food and beverage industry itself.
The University of Cincinnati's Susan McElroy, MD, told WVXU's Cincinnati Edition that a trial she led found that liraglutide, a drug in the GLP-1 class, was efficacious for weight loss for individuals with bipolar disorder and statistically reduced binge eating behavior based on self-reported data.
However, McElroy said that in general, it is difficult to conduct research focusing on GLP-1's effect on mental health and eating disorders.
"I’m just really sad that the GLP-1 companies haven’t taken eating disorders seriously," said McElroy, the Linda and Harry Fath endowed professor in the Department of Psychiatry & Behavioral Neuroscience in UC’s College of Medicine, chief research officer at the Lindner Center of HOPE and a UC Health physician.
Anecdotally, McElroy said some patients have reported GLP-1s triggering anorexia, while others say the drugs have been the only solution to address binge eating disorder. The wide range of outcomes highlights the need for more thorough research, she said.
"The industry has basically ignored eating disorders," she said. "I guess they assume that by getting at obesity they’re going to get most of the people with eating disorders, but that’s just not the truth."
Listen to the Cincinnati Edition segment.
Featured photo at top of a semaglutide injection pen. Photo/aprott/iStock.
Related Stories
U.S. News & World Report: Metformin may help young patients with bipolar disorder avoid weight gain
October 31, 2023
U.S. News & World Report highlighted recent research led by the University of Cincinnati and Northwell Health that found the drug metformin can help prevent or reduce weight gain in youth taking medication to treat bipolar disorder.
Cape Girardeau, Missouri news highlights UC clinical trial
February 20, 2024
KFVS-TV in Cape Girardeau, Missouri highlighted a University of Cincinnati clinical trial testing a wearable neurostimulation device to help patients with opioid use disorder and post-traumatic stress disorder stick with medication treatment while finding the right dose.
UC, Children's join $20 million statewide research effort
August 16, 2024
![Cincinnati Business Courier logo](/content/dam/refresh/uc-news/news-icons/dark/cin-business-courier.png)
The Cincinnati Business Courier highlighted the University of Cincinnati and Cincinnati Children’s being part of a collaborative research initiative designed to identify the root causes of the ongoing epidemic of persistent emotional distress, suicide and drug overdose in the state of Ohio.